Clinical Trial Update: Phase II Study of Irinotecan and Panitumumab [Phase 2]

View source ↗

Summary

Phase II study evaluating the combination of irinotecan and panitumumab in esophageal cancer has completed and posted its results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer

Drugs mentioned

• Irinotecan (Irinotecan)
• Panitumumab (panitumumab)

Snippet

Sponsor: Weijing Sun, MD, FACP | Conditions: Esophageal Cancer | Phase 2 | Status: COMPLETED | Results posted: 2016-11-15